-
Cotation en bourse
-
Trading
Where European Government Bonds meet the futureFixed Income derivativesLire la suiteTrade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo ClearingLire la suiteEuronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLire la suiteEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lire la suiteThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLire la suiteThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lire la suiteShaping capital markets for future generations
Introduction en bourse de Theranexus
30/10/2017
Introduction en bourse de Theranexus sur Euronext Growth
Franck Mouthon et Mathieu Charvériat, fondateurs de Theranexus, ouvrent les marchés à Paris
Theranexus is an innovative biopharmaceutical company specializing in the development of therapeutic products for the treatment of central nervous system diseases. Theranexus now has one product (THN102; a drug candidate combining a modulator of neuronal activity with a glial connexin modulator for the treatment of narcolepsy, a rare neurological disease) in Phase II clinical trial.
Theranexus est une société biopharmaceutique innovante spécialisée dans le développement de produits thérapeutiques destinés au traitement des maladies du système nerveux central. Theranexus dispose d’un produit en essai clinique de phase II (le THN102 ; un candidat médicament associant un modulateur de l’activité neuronale avec un modulateur des connexines gliales pour le traitement de la narcolepsie, une maladie neurologique rare)